Abstract:Immune-related liver injuries are closely associated with the liver's fundamental state. Patients with advanced biliary tract carcinoma (BTC) have poor liver function. We evaluated the clinical data of immune-related liver injury in patients with advanced BTC and gastric cancer (GC) during immune checkpoint inhibitor (ICI) treatment between February 2019 and July 2022 at Peking University First Hospital. Twenty-five patients with advanced BTC were identified. Fifteen patients (60%) experienced immune-related liver injury during ICI treatment. We also evaluated the clinical status of patients with GC in another group receiving immunotherapy. The results demonstrated that the incidence of immune-related liver injury was higher in patients with BTC than in GC cancer (p=0.040). Multivariate analysis suggested that the type of malignant tumor and baseline liver function status were high-risk factors for grade 2 and higher immune-related liver injuries. Two patients were diagnosed with immune-related cholangitis. Both biliary enzymes can be decreased to a certain degree by corticosteroid and ursodeoxycholic acid (UDCA) therapy but are difficult to reduce to normal levels. Liver function normalized, and symptoms improved after local treatment for cholestasis (stent implantation or PTBD). We observed a higher incidence of immune-related liver injury after ICI treatment in patients with advanced BTC. Effect of baseline liver function on the incidence of liver injury associated with immunotherapy. Interventional therapy provides rapid relief from cholestasis and is an indispensable and effective approach to the treatment of immune-related cholangitis.

S2399 A Rare Case of Immune Checkpoint Cholangitis

Immune checkpoint inhibitor-induced cholangitis-a three-case series

Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data

S1303 Initial Histologic Presentations of Immune Checkpoint Inhibitor Colitis and Their Differential Disease Outcomes

S4271 Autoimmune Cholangitis: A Rare Case of Silent Liver Cirrhosis

S4304 Cholangitis Lenta and Giant Cell Hepatitis: A Unique Coexistence

S1271 A Retrospective Study of Treatment Options for Checkpoint-Inhibitor Colitis and Their Impact on Disease Outcomes

Immune Checkpoint Inhibitor-Induced Hepatic Injury: A Clinicopathologic Review

Hepatobiliary complications of immune checkpoint inhibitors in cancer

S2429 Diagnostic Challenges and Atypical Presentation of Cholangiocarcinoma in a Patient with Persistent Jaundice

Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma

Secondary Sclerosing Cholangitis due to Drugs With a Special Emphasis on Checkpoint Inhibitors

S4649 Post-COVID-19 Cholangiopathy: Vigilance and Diligence Required - A Case Report

S2495 IgG4-Related Sclerosing Cholangitis Presenting as Cholangiocarcinoma: A Diagnostic Challenge

S2421 Duct and Cover: A Case of Post-COVID-19 Cholangiopathy Requiring Biliary Cast Removal

S3034 Refractory Immune Checkpoint Inhibitor-Associated Colitis: Case Report

Severe Immune-Mediated Colitis Induced by Checkpoint Inhibitors in an Adolescent With Lynch Syndrome

S2711 Primary Biliary Cholangitis: A Peculiar Presentation

S2528 Uncommon Culprit: Pancreatitis & Biliary Stricture Revealed

Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study

S4547 Severe Immune Checkpoint Inhibitor Hepatitis: Case Report